Compare UAN & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UAN | URGN |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2008 | 2016 |
| Metric | UAN | URGN |
|---|---|---|
| Price | $121.56 | $29.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.29 |
| AVG Volume (30 Days) | 49.7K | ★ 814.8K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 7.91% | N/A |
| EPS Growth | ★ 61.98 | N/A |
| EPS | ★ 4.72 | N/A |
| Revenue | ★ $606,038,000.00 | $1,128,000.00 |
| Revenue This Year | N/A | $129.09 |
| Revenue Next Year | N/A | $70.96 |
| P/E Ratio | $26.32 | ★ N/A |
| Revenue Growth | ★ 15.36 | N/A |
| 52 Week Low | $81.18 | $3.61 |
| 52 Week High | $139.50 | $32.37 |
| Indicator | UAN | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 42.25 | 60.89 |
| Support Level | $120.05 | $17.96 |
| Resistance Level | $139.42 | $30.00 |
| Average True Range (ATR) | 4.66 | 1.88 |
| MACD | -0.98 | -0.17 |
| Stochastic Oscillator | 10.32 | 61.54 |
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.